Loading
PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process. Regulates angiogenesis by inhibiting the cAMP-dependent guanine nucleotide exchange factor RAPGEF3 and downstream phosphatidylinositol 3-kinase gamma-mediated signalling. Controls cardiac contractility by reducing cAMP concentration in cardiocytes.
Open Targets scores its association with cancer at 0.62 (direct and indirect evidence; datatypes literature 0.75, animal model 0.36, genetic association 0.16, clinical 0.96).
In plain words · PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
PDE3B (cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B) is an enzyme. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Myeloproliferative neoplasms and Essential thrombocythaemia.
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process.
No product in this corpus aims at PDE3B yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Specificity not established: no corpus medicine is aimed at it and the catalogues give it only the role drug-target; HPA finds the RNA tissue enhanced, which says where the protein sits but not whether the tumour differs from normal tissue. HPA PDE3B: RNA tissue enhanced (adipose tissue 61 nTPM); blood lineage group enriched (granulocytes 4 nTPM, T-cells 6 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Myeloid neoplasms); Open Targets associates it with 1 specific cancer type at or above 0.5 (essential thrombocythemia). (No rule of scripts/fetch-target-specificity.ts fired.)
Sources: Human Protein Atlas PDE3B tissue; Open Targets ENSG00000152270 associations
First described 1996. Earliest sequence paper UniProt cites for the protein: Miki et al, Genomics, 1996, "Characterization of the cDNA and gene encoding human PDE3B, the cGIP1 isoform of the human cyclic GMP-inhibited cyclic nucleotide phosphodiesterase family". Source.
Sources: HGNC HGNC:8779 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q13370 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000152270 (association with cancer (MONDO_0004992) 0.62; per-cancer scores at or above 0.5: myeloproliferative neoplasm 0.58, essential thrombocythemia 0.58 (GraphQL API, CC0))
Cyclic nucleotide phosphodiesterase with a dual-specificity for the second messengers cAMP and cGMP, which are key regulators of many important physiological process. Regulates angiogenesis by inhibiting the cAMP-dependent guanine nucleotide exchange factor RAPGEF3 and downstream phosphatidylinositol 3-kinase gamma-mediated signalling. Controls cardiac contractility by reducing cAMP concentration in cardiocytes. Location: Membrane (UniProt). Locus 11p15.2 (HGNC).
RNA: tissue enhanced (adipose tissue 61 nTPM), detected in many normal tissues. Blood: group enriched (granulocytes 4 nTPM, T-cells 6 nTPM).
No normal tissue stained high.
No cancer sample stained medium or high.
HPA PDE3B tissue · HPA PDE3B pathology · HPA protein class: FDA approved drug targets
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"PDE3B" OR ABSTRACT:"PDE3B" OR TITLE:"phosphodiesterase 3B" OR ABSTRACT:"phosphodiesterase 3B" OR TITLE:"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B" OR ABSTRACT:"cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B" OR TITLE:"HcGIP1" OR ABSTRACT:"HcGIP1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PDE3B, not a curated reading list.
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Essential thrombocythaemia (ET), Myeloproliferative neoplasms (PV, ET, myelofibrosis).
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Open Targets Platform.